EXELIXIS INC (EXEL) Stock Fundamental Analysis
NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD
Overall EXEL gets a fundamental rating of 8 out of 10. We evaluated EXEL against 555 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues. EXEL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make EXEL a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
EXEL had positive earnings in the past year.
In the past year EXEL had a positive cash flow from operations.
Each year in the past 5 years EXEL has been profitable.
EXEL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 22.68%, EXEL belongs to the top of the industry, outperforming 98.38% of the companies in the same industry.
EXEL's Return On Equity of 30.20% is amongst the best of the industry. EXEL outperforms 97.84% of its industry peers.
The Return On Invested Capital of EXEL (26.25%) is better than 98.56% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EXEL is below the industry average of 14.78%.
The last Return On Invested Capital (26.25%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.68% | ||
| ROE | 30.2% | ||
| ROIC | 26.25% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
1.3 Margins
With an excellent Profit Margin value of 27.99%, EXEL belongs to the best of the industry, outperforming 96.58% of the companies in the same industry.
In the last couple of years the Profit Margin of EXEL has declined.
EXEL has a Operating Margin of 35.43%. This is amongst the best in the industry. EXEL outperforms 98.56% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
EXEL has a Gross Margin of 96.78%. This is amongst the best in the industry. EXEL outperforms 96.58% of its industry peers.
In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 35.43% | ||
| PM (TTM) | 27.99% | ||
| GM | 96.78% |
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
Compared to 5 years ago, EXEL has less shares outstanding
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
EXEL has an Altman-Z score of 12.79. This indicates that EXEL is financially healthy and has little risk of bankruptcy at the moment.
EXEL's Altman-Z score of 12.79 is amongst the best of the industry. EXEL outperforms 88.83% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.79 |
ROIC/WACC2.73
WACC9.63%
2.3 Liquidity
EXEL has a Current Ratio of 3.50. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL's Current ratio of 3.50 is on the low side compared to the rest of the industry. EXEL is outperformed by 60.00% of its industry peers.
EXEL has a Quick Ratio of 3.44. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Quick ratio (3.44) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.5 | ||
| Quick Ratio | 3.44 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 205.56% over the past year.
EXEL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.65% yearly.
EXEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 24.50%.
Measured over the past years, EXEL shows a quite strong growth in Revenue. The Revenue has been growing by 17.51% on average per year.
EPS 1Y (TTM)205.56%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%175%
Revenue 1Y (TTM)24.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%30.62%
3.2 Future
Based on estimates for the next years, EXEL will show a very strong growth in Earnings Per Share. The EPS will grow by 25.80% on average per year.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 11.19% on average per year.
EPS Next Y23.6%
EPS Next 2Y19.76%
EPS Next 3Y22.02%
EPS Next 5Y25.8%
Revenue Next Year7.43%
Revenue Next 2Y9.22%
Revenue Next 3Y11.04%
Revenue Next 5Y11.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
EXEL is valuated rather expensively with a Price/Earnings ratio of 20.98.
EXEL's Price/Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.14% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.45, EXEL is valued a bit cheaper.
The Price/Forward Earnings ratio is 17.39, which indicates a rather expensive current valuation of EXEL.
EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 93.87% of the companies in the same industry.
EXEL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.98 | ||
| Fwd PE | 17.39 |
4.2 Price Multiples
96.04% of the companies in the same industry are more expensive than EXEL, based on the Enterprise Value to EBITDA ratio.
EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXEL is cheaper than 94.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.33 | ||
| EV/EBITDA | 12.68 |
4.3 Compensation for Growth
EXEL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
EXEL's earnings are expected to grow with 22.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.89
PEG (5Y)1.66
EPS Next 2Y19.76%
EPS Next 3Y22.02%
5. Dividend
5.1 Amount
No dividends for EXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
46.15
+1.85 (+4.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.07%
Inst Owner Change2.99%
Ins Owners2.2%
Ins Owner Change18.04%
Market Cap12.59B
Analysts76.92
Price Target42.14 (-8.69%)
Short Float %7.64%
Short Ratio6.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.83%
Min EPS beat(2)10.66%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)55.5%
Min EPS beat(4)10.66%
Max EPS beat(4)148.98%
EPS beat(8)6
Avg EPS beat(8)22.76%
EPS beat(12)9
Avg EPS beat(12)18.75%
EPS beat(16)12
Avg EPS beat(16)61.89%
Revenue beat(2)1
Avg Revenue beat(2)3.96%
Min Revenue beat(2)-1.38%
Max Revenue beat(2)9.31%
Revenue beat(4)3
Avg Revenue beat(4)12.55%
Min Revenue beat(4)-1.38%
Max Revenue beat(4)34.34%
Revenue beat(8)4
Avg Revenue beat(8)4.97%
Revenue beat(12)6
Avg Revenue beat(12)3.28%
Revenue beat(16)8
Avg Revenue beat(16)4.82%
PT rev (1m)8.88%
PT rev (3m)11.09%
EPS NQ rev (1m)0.86%
EPS NQ rev (3m)16.02%
EPS NY rev (1m)0.93%
EPS NY rev (3m)9.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.3%
Revenue NY rev (1m)-0.92%
Revenue NY rev (3m)3.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.98 | ||
| Fwd PE | 17.39 | ||
| P/S | 5.47 | ||
| P/FCF | 15.33 | ||
| P/OCF | 14.94 | ||
| P/B | 5.91 | ||
| P/tB | 6.09 | ||
| EV/EBITDA | 12.68 |
EPS(TTM)2.2
EY4.77%
EPS(NY)2.65
Fwd EY5.75%
FCF(TTM)3.01
FCFY6.52%
OCF(TTM)3.09
OCFY6.69%
SpS8.43
BVpS7.81
TBVpS7.58
PEG (NY)0.89
PEG (5Y)1.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.68% | ||
| ROE | 30.2% | ||
| ROCE | 33.41% | ||
| ROIC | 26.25% | ||
| ROICexc | 45.49% | ||
| ROICexgc | 47.65% | ||
| OM | 35.43% | ||
| PM (TTM) | 27.99% | ||
| GM | 96.78% | ||
| FCFM | 35.71% |
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score9
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 72.88% | ||
| Cap/Sales | 0.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 99.8% | ||
| Profit Quality | 127.55% | ||
| Current Ratio | 3.5 | ||
| Quick Ratio | 3.44 | ||
| Altman-Z | 12.79 |
F-Score9
WACC9.63%
ROIC/WACC2.73
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%175%
EPS Next Y23.6%
EPS Next 2Y19.76%
EPS Next 3Y22.02%
EPS Next 5Y25.8%
Revenue 1Y (TTM)24.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%30.62%
Revenue Next Year7.43%
Revenue Next 2Y9.22%
Revenue Next 3Y11.04%
Revenue Next 5Y11.19%
EBIT growth 1Y298.52%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year34.7%
EBIT Next 3Y31.16%
EBIT Next 5Y1.16%
FCF growth 1Y209.54%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y181.52%
OCF growth 3Y20.43%
OCF growth 5Y5.84%